Third Rock launches Sage with $35M Series A to address CNS pathways
This article was originally published in Scrip
Executive Summary
The latest start-up from the Third Rock Ventures stable, Sage Therapeutics, has been formally launched, to develop treatments for central nervous system disorders. With a Series A funding of $35 million, Sage will be basing its R&D on allosteric receptor modulation, where the goal is not to simply turn a receptor on or off, the way most drugs act, but to develop allosteric modulators that offer control over the intensity of receptor activation and thus restoring the balance to the activity of the primary excitatory and inhibitory neurotransmitter systems of the brain.